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Background: Chronic pain is a global health problem, affecting around 1 in 5 individuals in the general population. The
understanding of the key role of functional brain alterations in the generation of chronic pain has led researchers to focus on pain
treatments that target brain activity. Electroencephalographic neurofeedback attempts to modulate the power of maladaptive
electroencephalography frequency powers to decrease chronic pain. Although several studies have provided promising evidence,
the effect of electroencephalographic neurofeedback on chronic pain is uncertain.
Objective: This systematic review aims to synthesize the evidence from randomized controlled trials to evaluate the analgesic
effect of electroencephalographic neurofeedback. In addition, we will synthesize the findings of nonrandomized studies in a
narrative review.
Methods: We will apply the search strategy in 5 electronic databases (Cochrane Central Register of Controlled Trials, MEDLINE,
EMBASE, PsycInfo, and CINAHL) for published studies and in clinical trial registries for completed unpublished studies. We
will include studies that used electroencephalographic neurofeedback as an intervention for people with chronic pain. Risk-of-bias
tools will be used to assess methodological quality of the included studies. We will include randomized controlled trials if they
have compared electroencephalographic neurofeedback with any other intervention or placebo control. The data from randomized
controlled trials will be aggregated to perform a meta-analysis for quantitative synthesis. The primary outcome measure is pain
intensity assessed by self-report scales. Secondary outcome measures include depressive symptoms, anxiety symptoms, and sleep
quality measured by self-reported questionnaires. We will investigate the studies for additional outcomes addressing adverse
effects and resting-state electroencephalography analysis. Additionally, all types of nonrandomized studies will be included for
a narrative synthesis. The intended and unintended effects of nonrandomized studies will be extracted and summarized in a
descriptive table.
Results: Ethics approval is not required for a systematic review, as there will be no patient involvement. The search for this
systematic review commenced in July 2020, and we expect to publish the findings in early 2021.
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Conclusions: This systematic review will provide recommendations for researchers and health professionals, as well as people
with chronic pain, about the evidence for the analgesic effect of electroencephalographic neurofeedback.
Trial Registration: International Prospective Register of Systematic Reviews (PROSPERO) CRD42020177608;
https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=177608
International Registered Report Identifier (IRRID): PRR1-10.2196/22821
(JMIR Res Protoc 2020;9(10):e22821) doi: 10.2196/22821
KEYWORDS
EEG neurofeedback; chronic pain; meta-analysis; systematic review
Introduction
Background
Chronic pain is estimated to affect up to 50% of the adult
population [1,2], and 10% to 20% experience clinically
significant chronic pain [3]. Chronic pain is defined as ongoing
or recurrent pain, lasting for at least three months [4,5]. It is
often associated with functional limitations and psychological
distress [4,6], resulting in a decreased health-related quality of
life [7,8]. Chronic pain may result from an ongoing pathology
(eg, cancer), damage to the central nervous system (eg, stroke
and spinal cord injury) or peripheral nervous system (eg, diabetic
neuropathy), tissue degeneration (eg, arthritis), and other pain
syndromes with unknown pathologies (eg, fibromyalgia and
complex regional pain syndrome).
The understanding of the critical role of maladaptive functional
brain changes in the development and maintenance of chronic
pain has led researchers to focus on pain treatments that aim to
modulate brain activity [9,10]. Previously, neurosurgical
methods, such as cordotomy and thalamotomy, were considered
to be effective in the control of abnormal brain activity, such
as increased theta frequency power, resulting in a significant
pain reduction [11,12]. However, these types of surgery are
costly, highly invasive, and associated with major complications
such as cognitive impairment. In the past few decades,
noninvasive brain stimulation techniques including transcranial
direct current stimulation, cranial electrotherapy stimulation,
and repetitive transcranial magnetic stimulation have been used
to reduce pain by aiming to alter the maladaptive brain activity
associated with chronic pain. However, there is insufficient
evidence to support the efficacy of these approaches on chronic
pain [13,14]. More recently, electroencephalographic (EEG)
neurofeedback using brain-computer interface technology has
been developed to target the maladaptive brain activity
underlying chronic pain [2,15].
Description of EEG Neurofeedback
The goal of EEG neurofeedback is to modulate the targeted
maladaptive EEG frequency powers to decrease chronic pain
[2,15,16]. Surface EEG is recorded from 1 or more electrode
sites, depending on the specific pain condition, often from the
sensorimotor cortex [17]. The targeted frequency powers are
extracted and processed in real time, then presented to the
individual as visual or auditory feedback, or both [16,18]. For
example, it has been shown that individuals with chronic
neuropathic pain have increased theta and reduced alpha
frequency power compared with healthy individuals without
chronic pain [19,20]. In this case, EEG neurofeedback is used
to suppress theta and reinforce alpha frequency power [2,16].
Using this EEG neurofeedback protocol, individuals can learn
to regulate their abnormal brain activity in a way that reduces
their chronic pain [2,16].
Previous Reviews and Rationale
Previous systematic reviews about the effect of EEG
neurofeedback on chronic pain have mainly focused on specific
pain conditions such as fibromyalgia [21,22] or cancer-related
pain [23]. The results of these systematic reviews were
inconclusive due to the limited data. While a recent review
found a medium effect size of pain reduction favoring
neurofeedback interventions in chronic pain, it included studies
using functional magnetic resonance imaging-based
neurofeedback [24]. Combining the results for 2 different
methodologies makes it difficult to evaluate the analgesic effect
of a specific intervention.
Our planned systematic review will cover all forms of chronic
pain and include only EEG-based neurofeedback interventions
to increase the likelihood of conclusive evidence about the
analgesic effect of EEG neurofeedback. Although inclusion of
a wide variety of pain conditions will increase the heterogeneity
of the pooled data, the larger sample size will substantially
improve the meta-analytic power. In order to distinguish the
effect of EEG neurofeedback on different chronic pain types,
such as neuropathic and nonneuropathic pain, we will conduct
a subgroup analysis (see the Subgroup and Sensitivity Analysis
subsection below). Review findings will inform researchers and
health professionals, as well as people with chronic pain, about
the analgesic effect of EEG neurofeedback. In addition, this
review can help to identify any gaps in previous studies and
provide direction for future research.
Objectives
The primary objective of this systematic review is to evaluate
the evidence for the analgesic effect of EEG neurofeedback for
people with chronic pain. The secondary objective is to
investigate the effect of EEG neurofeedback on depressive
symptoms, anxiety symptoms, and sleep quality. Further, as an
additional objective of this systematic review, we will include
the reports of adverse events and resting-state EEG analysis for
a narrative review.
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This systematic review protocol is prepared according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analysis Protocols (PRISMA-P) 2015 guidelines [25,26].
Multimedia Appendix 1 is the PRISMA-P checklist. This
systematic review is registered in the International Prospective
Register of Systematic Reviews with registration number
CRD42020177608.
Types of Participants
We will include studies of participants with chronic pain,
defined as persistent or recurrent pain for more than 3 months
[4]. There will be no restriction on age or sex of the participants
in the included studies.
Types of Intervention
We will include studies that investigate the analgesic effect of
EEG neurofeedback for people with chronic pain, regardless of
the number and duration of intervention sessions, the EEG
neurofeedback protocol, and the targeted brain region.
Types of Outcome Measures
The primary outcome measure is pain intensity. Pain intensity
may be assessed using a self-report rating scale such as the
visual analog scale or the numeric rating scale. Studies that used
other scales will also be included.
The secondary outcome measures are depressive symptoms,
anxiety symptoms, and sleep quality. Depressive symptoms and
anxiety symptoms may be measured by self-report
questionnaires such as the Beck Depression Inventory or Beck
Anxiety Inventory, or the Hamilton Depression Rating Scale
or Hamilton Anxiety Rating Scale. Sleep quality may be
assessed using the Medical Outcomes Study Sleep Scale or the
Pittsburgh Sleep Quality Index. Studies that have used other
assessments will not be excluded.
We will include studies that have assessed the primary or
secondary outcome measures, or both, on at least two occasions,
one before or at the beginning of the intervention and one close
to or at the end of the intervention. Further, we will include
additional outcome measures for the narrative review. For
example, reports of any adverse effects will be included as well
as the results of the resting-state EEG analysis comparing pre-
versus postintervention.
Types of Studies
We will include randomized controlled trials (RCTs) if they
have compared EEG neurofeedback with no treatment or any
other intervention, including sham control, waitlist control, or
usual care. Nonrandomized studies, defined as “any quantitative
study estimating the effectiveness of an intervention that does
not use randomisation to allocate subjects to comparison groups”
[27], will be included for a narrative review. Comparative
nonrandomized studies (eg, cross-sectional designs and
controlled cohort studies) will be used to address intended
effects, and noncomparative studies (eg, case reports and case
series) will be reported for corroborating evidence and adverse
effects. All studies must have used EEG neurofeedback as an
intervention for people with chronic pain. We will exclude
studies that involved the following: (1) individuals experiencing
pain for less than 3 months; (2) healthy individuals with
experimentally induced pain; and (3) any other intervention in
conjunction with EEG neurofeedback.
Search Strategy
To identify the eligible studies, we will search 5 electronic
bibliographic databases for published studies: (1) Cochrane
Central Register of Controlled Trials (CENTRAL), (2)
MEDLINE, EMBASE, and PsycInfo via Ovid, and (3) CINAHL
via EBSCO.
Additionally, we will search the following clinical trial registries
for completed unpublished studies: (1) ClinicalTrials.gov, (2)
EU Clinical Trials Register, (3) Australia New Zealand Clinical
Trials Registry, and (4) World Health Organization International
Clinical Trials Registry Platform (ICTRP).
Search strategies will be established using Medical Subject
Headings (MeSH) and related text words. We will use a
combination of different keywords for chronic pain and EEG
neurofeedback intervention to identify relevant literature. The
search strategies will be tailored to each database. Multimedia
Appendix 2 shows the search strategy according to Ovid search
syntax. There will be no restriction on the publication period,
but only articles in English language will be included. In
addition, we will check the reference lists of the eligible studies
and relevant review articles to include any missed but relevant
published studies. While the review is in progress, citation
searching for forward citation of recent studies and citation
alerts (eg, on Google Scholar) on included studies will be used
to identify new studies as they appear. The searches will be
rerun prior to the final analysis and further retrieved studies will
be included.
Study Selection
We will use EndNote X9 (Clarivate Analytics) reference
software to store, organize, and manage all the search results
and ensure an efficient study selection process by removing the
duplicate records. Two reviewers will independently evaluate
the title and abstract of all studies identified through the search
against the inclusion and exclusion criteria. Any disagreement
between the individual judgments will be resolved by an
additional reviewer. The screening process will be conducted
in Covidence (Veritas Health Innovation Ltd), which is
systematic review management software. The full text of the
selected studies will then be retrieved. In the case of trial
registrations, the full text is defined as all associated files and
information. If the reviewer is uncertain about the eligibility of
any study, the full text will be obtained for further information.
An additional reviewer will be consulted, should there be any
uncertainty or disagreement of the eligibility of studies.
Disagreement on study eligibility will be resolved through
consensus. Excluded studies and the reasons for exclusion will
be recorded and documented.
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We will pilot test a customized data extraction spreadsheet on
2 studies relevant to this review, and then use it to extract data
from the eligible studies. Two reviewers will independently
extract the data from the final list of studies. The disagreements
in the extracted data will be resolved through discussion with
an additional reviewer. The following information will be
extracted from the eligible studies.
We will extract data on study characteristics, including the
study design, country, and setting of the study.
We will extract participant data on diagnosis, age, sex, duration
of pain, comorbidities, and the number of participants allocated
in each intervention group. The primary and secondary outcome
measures at baseline (ie, before or at the beginning of the
intervention) will also be extracted (mean and measure of
variability).
We will extract intervention data on EEG neurofeedback
protocols including the targeted frequency bands, the targeted
brain region, the duration of each session, the number of
sessions, and the duration of the interventions. Data on the
details of the comparative intervention (ie, type, dosage,
frequency) in each individual study will also be extracted.
We will extract data on the type of outcome measures used to
assess the primary and secondary outcomes, the time points
from baseline to the end of interventions, and follow-ups. The
postintervention assessments will be categorized into 3 groups:
short-term for less than 1 week, mid-term for 1 to 6 weeks, and
long-term for more than 6 weeks for follow-up assessments.
We will extract results of the primary and secondary outcome
measures at a time point close to or at the end of the
interventions, or the changes in outcome measures from baseline
for each intervention group. If a study used more than 1 outcome
measure of pain intensity, we will select and extract only a
single measure, prioritizing them in the following order:
100-mm/10-cm visual analog scale, 11-point numeric rating
scale (0 = no pain, 10 = the worst pain imaginable), and then
pain intensity rating from composite measures or other scales
[28].
For the secondary outcome measures, we will extract scores
from each of the questionnaires for depressive symptoms,
anxiety symptoms, and sleep quality if the studies used more
than 1 questionnaire. We will also extract the number of
participants who stopped receiving the treatment due to a rare
or adverse event in each intervention group.
If data are missing, we will contact the authors of the studies a
maximum of 3 times, after which we will consider the data to
be irretrievable.
Study Quality and Risk of Bias
Study quality and risk of bias will be assessed by 2 independent
reviewers using the first version of the Cochrane Risk of Bias
(RoB 1.0) tool for RCTs [29] and the Cochrane Risk of Bias in
Non-Randomised Studies - of Interventions (ROBINS-I) tool
for nonrandomized studies [30]. Additionally, the quality of
noncomparative studies (eg, case reports and case series) will
be assessed using the Joanna Briggs Institute critical appraisal
tools [31]. The inconsistencies will be resolved by an additional
reviewer.
We will use the Cochrane RoB 1.0 tool to assess the study-level
risk of bias for 5 domains: selection, performance, detection,
attrition, and reporting bias [29]. We will use the ROBINS-I
tool to assess the risk of bias for studies that have not used
randomization for intervention allocations, such as cohort studies
and cross-sectional designs. The risk-of-bias assessment using
this tool covers 7 domains: confounding and participants’
selection (preintervention), intervention classification (during
intervention), and deviations, missing data, measurements, and
selection of reported results (postintervention) [30]. The
ROBINS-I tool includes signaling questions to provide easier
judgments for each domain, as well as an overall risk-of-bias
assessment. We will use the Joanna Briggs Institute critical
appraisal checklists [31] for case reports and case series to assess
the study-level risk of bias.
Data Synthesis
We will not combine the data extracted from RCTs and
nonrandomized studies for a quantitative synthesis. The
distinctions between various types of nonrandomized studies
and RCTs make it methodologically indefensible to pool the
results in a meta-analysis [32]. The extracted outcomes data
from RCTs will be quantitatively synthesized by a meta-analysis
method using R (R version 4.0.0; R Foundation for Statistical
Computing) software. The population and intervention from at
least two RCTs must be sufficiently similar to perform a
meta-analysis. Indeed, the level of consistency and
appropriateness of RCTs is key to justify pooling the results in
a meta-analysis [33].
We will convert the primary and secondary outcome data to a
0- to 100-point scale (mean and standard deviation) [28]. In
numerical or continuous scales, the score value is divided by
the range of scale, and then multiplied by 100. For example,
for a 0 to 20 scale, the score value is divided by 20 and
multiplied by 100. Likert scales will be treated as numerical
scales, because the scores for Likert-type questions can be
summed and presented as a final scale score. Additionally, in
categorical scales, the lowest value will be assigned to be 0,
and then 1 additional point for each category of severity. For
example, none = 0, mild = 1, moderate = 2, and high = 3. Then,
these values will be treated like numerical scales.
The relative treatment effects of the compared interventions
(eg, EEG neurofeedback vs control) on the outcome measures
will be estimated using weighted mean difference with 95%
confidence intervals [28]. We will use a threshold of 10 points
on the 0- to 100-point scale to clarify the minimal clinically
important effect of EEG neurofeedback on pain intensity [34].
Since a cutoff threshold has not been established for converted
0 to 100 points of the secondary outcomes, we will adopt a
10-point threshold as the clinically meaningful change for
depressive symptoms, anxiety symptoms, and sleep quality.
In recognition of the likely heterogeneity of the chronic pain
population and the EEG neurofeedback methodology, we will
use a random-effects meta-analysis. We will assess the
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heterogeneity of the study population and intervention using
the χ2 test and estimate the degree of heterogeneity using the
I
2 statistic. The heterogeneity is considered significant when
P<.1 and when I2≥50%. A subgroup analysis will be performed
when significant heterogeneity is present (see Subgroup and
Sensitivity Analysis subsection).
We will conduct a narrative synthesis to provide additional
information about EEG neurofeedback as an intervention
including adverse effects. The data and methodology for the
great variety of nonrandomized designs are usually not
sufficiently similar to be pooled in a meta-analysis; thus, we
will use a narrative approach for these studies [35]. Narrative
methods of synthesis include classification of evidence from
diverse studies, data reduction, data display, comparison, and
conclusion [36]. The findings from the nonrandomized studies
will be described and summarized in an extraction table using
techniques of narrative synthesis.
Quality of Evidence
We will use the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach [37] to grade
the certainty of evidence and the strength of recommendations
at the outcome level. For example, the GRADE rating will be
applied to the outcome of interest to estimate the certainty of
the intervention effect. There are 4 levels of certainty within
the GRADE approach: very low, low, moderate, and high. The
level of certainty of evidence can be downgraded for the
following reasons.
Risk of Bias
The rating will be downgraded by 2 levels if there is a high risk
of bias for more than 25% and less than 50% of the included
studies’ participants. It will be 1 grade down if more than 50%
of participants are from high risk-of-bias studies [38].
Imprecision
The rating will be downgraded by 1 level if the total number of
participants is less than 400 for continuous data and less than
300 for dichotomous data [39].
Inconsistency
The rating will be downgraded by 1 level if significant
heterogeneity is identified (P<.1) [40].
Indirectness
This domain will not be considered because the inclusion criteria
of this review ensures a specific population and outcome interest
[41].
Publication Bias
The rating will be downgraded by 1 level if a publication bias
is detected using visual and statistical assessments [42].
Subgroup and Sensitivity Analysis
Where heterogeneity is identified (P<.1), we will conduct
subgroup analysis according to the type of chronic pain and the
study population age through preplanned analysis: (1)
neuropathic pain versus nonneuropathic pain: neuropathic pain
is defined as “pain caused by a lesion or disease of the
somatosensory nervous system” [43], and nonneuropathic pain
includes all other chronic pain conditions; (2) adults versus
adolescents or children: studies including adults over 18 years
old compared with studies with individuals under 18 years old.
Further, depending on the variability of RCTs, we will conduct
a sensitivity analysis to assess the impact of excluding studies
with high risk of bias.
Results
This review will not require any ethics approval, as there will
be no patient involvement in the conduct, reporting, and
interpretation of the review. The search for this systematic
review commenced in July 2020, and we will disseminate the
findings as soon as they are available, expected by early 2021.
Discussion
This protocol describes the methodology of a systematic review
and meta-analysis to aggregate the evidence for analgesic effects
of EEG neurofeedback for people with chronic pain. In addition
to including RCTs for a meta-analysis, we will supplement the
review by a narrative synthesis of nonrandomized comparative
designs for intended effects and noncomparative designs for
corroborating evidence and adverse effects.
The heterogeneity of the chronic pain population and the variety
of EEG neurofeedback methodology might restrict the
opportunities for meta-analysis and interpretation of results.
However, preplanned subgroup analyses based on the pain
conditions and patients’ age groups will help to address the
issue of population heterogeneity.
We will report the methodology and results of this review
according to the PRISMA guidelines [44]. The findings will
provide an evaluation of both the intended and adverse effects
of EEG neurofeedback interventions. Given the debilitating
impact of chronic pain on people’s quality of life, this systematic
review will provide recommendations for researchers, health
care professionals, and people with chronic pain about the
evidence for the analgesic effect of EEG neurofeedback.
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